Navigation Links
Millennium Discovers Biomarkers Potentially Predictive of Response,to Velcade (Bortezomib) for Injection

re sensitive to VELCADE therapy. Additionally, these findings showed that the biomarkers did not predict sensitivity to dexamethasone therapy, indicating that the biomarkers may be specific to VELCADE.

"Millennium is recognized as a leader in personalized medicine, and this publication is a testament to the strength of our clinical innovation," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "The genomic findings add further knowledge about VELCADE efficacy in treating a broad range of multiple myeloma patients."

Millennium and its co-development partner, Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) is continuing genomics research on VELCADE in additional trials. Studies include a Phase III trial conducted by the Dutch and German co-operative groups, HOVON and GMMG, which is evaluating a VELCADE based combination in patients with newly diagnosed multiple myeloma. In addition, genomics research is ongoing in a Phase III trial evaluating a VELCADE based combination therapy in indolent non-Hodgkin's lymphoma.

"While the published results represent an important step forward in our genomics research, the next critical step is to conduct similar analyses with VELCADE in combination with other anti-cancer agents," said George Mulligan PhD, Associate Director, Translational Medicine, Millennium. "We are committed to improving outcomes for multiple myeloma patients and this work should bring us closer to determining optimal treatment strategies."

About VELCADE

VELCADE is being co-developed by Millennium and J&JPRD. Millennium is responsible for commercialization of VELCADE in the U.S.; Janssen-Cilag is responsible for commercialization in Europe and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan. For a limited period of time, Millennium and Ortho Biotech Inc. are co-promoting VELCADE in the U.S. VELCADE is approved in more than 80 count
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Research Supported by Samuel Waxman Cancer Research Foundation Discovers Mode of Action of Arsenic-Based Drugs in Destroying Cancer Cells
2. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
3. Survey: Migraine Patients Taking Potentially Addictive Barbiturate or Opioid Medications Not Approved by FDA as Migraine Treatments
4. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
5. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
6. Indivumed Study Provides Sound Scientific Basis for a Predictive Drug Test- Platform
7. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
8. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
9. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
10. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
11. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
Post Your Comments:
(Date:8/21/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a multivariate ... has appointed Holly B. Bauzon as Vice ... Bauzon has a proven track record in both increasing ... companies. She has more than 20 years of healthcare ... the position of Director, Lab Services Sales and Managed ...
(Date:8/21/2014)... 21, 2014 The spinal column is one of ... Signals carried to and from the brain through the column ... system. Injury or ailment here can be life altering, and ... of control over their body. Though back injury and disease ... there are more options available to make things better than ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance ... comic series designed to educate children about the most common ... Medikidz Explain Epilepsy comic series tells a fictional ... navigating middle school while living with epilepsy. ... there is still so much misinformation and lack of awareness ...
Breaking Medicine Technology:Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3
... , MINNEAPOLIS, Dec. 29 Target® announces ... seven Target Clinic locations in Maryland, while supplies last. ... will be available daily at Target Clinic locations during clinic ... cover the cost). For information on which stores ...
... , , MOUNTAIN VIEW, Calif., Dec. 29 ... developing innovative, next-generation medical therapies to address unmet needs in ... Drug Application (NDA) has been submitted to the U.S. Food ... drug for the treatment of obesity, including weight loss and ...
Cached Medicine Technology:VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 2VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 3VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 4VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity 5
(Date:8/23/2014)... Albany, New York (PRWEB) August 23, 2014 ... invasive surgeries done to remove plaques, etc, thereby addressing ... surgeries restore the flow of blood to the other ... the flow of oxygenated blood. These procedures require the ... made of metal composites and polymers), these catheters are ...
(Date:8/23/2014)... PA (PRWEB) August 23, 2014 Having been ... and dental hygienist from Arlington, Texas, saw a need for ... and toothpaste. "That’s when I came up with the idea ... No-Brush provides an effective way for a user to clean ... need to carry multiple items. It also helps avoid plaque ...
(Date:8/23/2014)... (PRWEB) August 23, 2014 A team of ... mesothelioma last longer when preceded by surgery and delivered by ... on the new study. Click here to read it ... studied the cases of mesothelioma patients who underwent ... conforming radiotherapy dose to the shape of a tumor. ...
(Date:8/23/2014)... August 23, 2014 Legal Insider ... created by Greg Marks has been generating a buzz ... month. The commotion surrounding the new product has drawn ... review. , “In recent years the market ... systems, commonly referred to as robots or ‘bots,'” reports ...
(Date:8/23/2014)... GBI Research, the leading business intelligence ... in Major Developed Markets to 2020 - New and ... which provides in-depth analysis of the critical care market ... and Canada. The report provides an estimation of market ... It covers critical care indications that are being treated ...
Breaking Medicine News(10 mins):Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Health News:Global Peripheral Intervention Market: Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 4Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:Legal Insider Bot Review Examining Greg Marks’ Trading Software Released 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 2Health News:Critical Care Therapeutics in Major Developed Markets to 2020 | Researchmoz 3
... Southeast Florida Market, NORTH HOLLYWOOD, Calif., Aug. ... IPCM ), a leading national hospitalist,physician group practice, ... of Hospitalists of America (HOA). The acquisition,expands IPC,s ... with a network of independent physicians, who perform ...
... InteKrin Therapeutics, Inc.,a clinical stage biopharmaceutical company ... and obesity today announced it has,completed the first ... $18.25,million. The financing was led by Skyline Ventures ... Ph.D. of Skyline will join InteKrin,s Board of,Directors. ...
... (Nasdaq:,EVVV), a global endovascular device company, today announced the,appointment ... effective,immediately. Mr. Kohrs will also serve as a member ... director of ev3 from June 2005,until October 2007 at ... the completion of ev3,s acquisition of FoxHollow Technologies,Inc., ...
... the Virginia Bioinformatics Institute (VBI) at Virginia Tech have ... proteins in oomycete plant pathogens that enables the proteins ... region contains the amino acid sequence motifs RXLR and ... proteins across the membrane surrounding plant cells without any ...
... less rest linked to doubled chance of weight gain, study ... little sleep or not spending enough time in rapid eye ... and teens, a new U.S. study. , For three consecutive ... 7 to 17. They looked at total sleep time, time ...
... Study finds that older patients, concerns often go unspoken and ... ... surgery with,their orthopaedic surgeons, older patients frequently do not raise all of,their ... The Journal of Bone and Joint Surgery found that patients age,60 or ...
Cached Medicine News:Health News:IPC The Hospitalist Company Completes Acquisition of Hospitalists of America 2Health News:InteKrin Therapeutics Announces $20 Million Series C Financing 2Health News:ev3 Inc. Appoints Douglas W. Kohrs to Board of Directors 2Health News:Key to virulence protein entry into host cells discovered 2Health News:Kids Who Sleep Poorly at Risk for Being Overweight 2Health News:Video: Communication is Key to Ease Worry about Orthopaedic Surgery 2Health News:Video: Communication is Key to Ease Worry about Orthopaedic Surgery 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: